Ocugen (OCGN) Competitors $0.71 -0.01 (-0.70%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OCGN vs. AVBP, COGT, RLAY, PAHC, CDMO, SANA, AVDL, TYRA, SEPN, and CRONShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Relay Therapeutics (RLAY), Phibro Animal Health (PAHC), Avid Bioservices (CDMO), Sana Biotechnology (SANA), Avadel Pharmaceuticals (AVDL), Tyra Biosciences (TYRA), Septerna (SEPN), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Ocugen vs. ArriVent BioPharma Cogent Biosciences Relay Therapeutics Phibro Animal Health Avid Bioservices Sana Biotechnology Avadel Pharmaceuticals Tyra Biosciences Septerna Cronos Group ArriVent BioPharma (NASDAQ:AVBP) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk. Does the media refer more to AVBP or OCGN? In the previous week, Ocugen had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 4 mentions for Ocugen and 3 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.91 beat Ocugen's score of 0.26 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor AVBP or OCGN? Ocugen received 92 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 70.13% of users gave Ocugen an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes16100.00% Underperform VotesNo VotesOcugenOutperform Votes10870.13% Underperform Votes4629.87% Do insiders and institutionals have more ownership in AVBP or OCGN? 9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 4.3% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable valuation and earnings, AVBP or OCGN? Ocugen has higher revenue and earnings than ArriVent BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33MN/AN/AOcugen$6.04M34.24-$63.08M-$0.18-3.94 Do analysts recommend AVBP or OCGN? ArriVent BioPharma presently has a consensus price target of $36.80, suggesting a potential upside of 50.76%. Ocugen has a consensus price target of $5.67, suggesting a potential upside of 698.12%. Given Ocugen's higher probable upside, analysts clearly believe Ocugen is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AVBP or OCGN more profitable? ArriVent BioPharma has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. ArriVent BioPharma's return on equity of -43.89% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Ocugen -532.51%-154.75%-90.79% SummaryOcugen beats ArriVent BioPharma on 7 of the 13 factors compared between the two stocks. Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$206.84M$2.96B$5.21B$9.14BDividend YieldN/A1.91%5.13%4.02%P/E Ratio-3.9445.5689.4217.36Price / Sales34.24275.871,240.0477.11Price / CashN/A192.9043.7535.97Price / Book4.443.965.314.79Net Income-$63.08M-$41.02M$122.54M$225.00M7 Day Performance-2.74%1.13%1.42%2.37%1 Month Performance-7.79%-1.72%2.50%4.40%1 Year Performance38.67%-2.23%25.29%20.10% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen2.3251 of 5 stars$0.71-0.7%$5.67+698.1%+38.7%$206.84M$6.04M-3.9480AVBPArriVent BioPharma1.3658 of 5 stars$24.98+0.4%$36.80+47.3%N/A$841.75MN/A0.0040Short Interest ↑COGTCogent Biosciences1.5529 of 5 stars$7.62-2.8%$14.83+94.7%+74.9%$841.72MN/A-3.0780Short Interest ↑Positive NewsRLAYRelay Therapeutics2.4277 of 5 stars$4.91+10.3%$20.50+317.5%-56.2%$821.85M$10.01M-1.88330PAHCPhibro Animal Health4.2357 of 5 stars$20.12+0.3%$20.50+1.9%+88.1%$814.92M$1.05B46.791,860Analyst RevisionCDMOAvid Bioservices2.2624 of 5 stars$12.43+0.2%$12.25-1.4%+99.8%$795.06M$150.45M-5.20320SANASana Biotechnology3.0545 of 5 stars$3.45-5.7%$14.25+313.0%-37.5%$770.28MN/A-2.46380AVDLAvadel Pharmaceuticals3.5385 of 5 stars$7.89-0.1%$22.00+178.8%-48.3%$760.30M$138.16M-9.9970TYRATyra Biosciences2.6241 of 5 stars$15.00-1.3%$30.50+103.3%+23.3%$759.05MN/A-9.3220SEPNSepterna1.6595 of 5 stars$17.00-5.5%$43.67+156.9%N/A$754.85M$981,000.000.00N/ACRONCronos Group2.582 of 5 stars$1.96-1.0%$3.00+53.1%-0.5%$749.30M$111.23M-15.08450Short Interest ↓News CoveragePositive News Related Companies and Tools Related Companies ArriVent BioPharma Alternatives Cogent Biosciences Alternatives Relay Therapeutics Alternatives Phibro Animal Health Alternatives Avid Bioservices Alternatives Sana Biotechnology Alternatives Avadel Pharmaceuticals Alternatives Tyra Biosciences Alternatives Septerna Alternatives Cronos Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCGN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
